Author:
Dymond Angela W.,So Karen,Martin Paul,Huang Yifan,Severin Paul,Mathews David,Lisbon Eleanor,Mariani Gabriella
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,General Medicine
Reference19 articles.
1. Yeh TC, Marsh V, Bernat BA et al (2007) Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res 13(5):1576–1583
2. ClinicalTrials.gov (2015) Study comparing complete remission after treatment with selumetinib/placebo in patient with differentiated thyroid cancer (ASTRA) (NCT01843062). 2015. Available from: https://clinicaltrials.gov/ct2/show/NCT01843062 . [11 Dec 2015]
3. Widemann, B.C., L.J. Marcus, M.J. Fisher et al., Phase I study of the MEK1/2 inhibitor selumetinib (AZD6244) hydrogen sulfate in children and young adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PNs). in J Clin Oncol. 2014. p. Abstract 10018.
4. Miyamoto M, Yamashita T, Yasuhara Y et al (2015) Membrane anchor of cytochrome P450 reductase suppresses the uncoupling of cytochrome P450. Chem Pharm Bull (Tokyo) 63(4):286–294
5. Sevrioukova IF, Poulos TL (2015) Current approaches for investigating and predicting cytochrome P450 3A4-ligand interactions. Adv Exp Med Biol 851:83–105
Cited by
26 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献